Investor Newsletter

Issue 11 2021

MicroPort®

MicroPort® Establishes Headquarters for the Americas in USA, with Southern California Innovation Center and Intelligent Manufacturing Base

MicroPort Scientific Corporation (MicroPort®) recently announced to establish 'MicroPort Scientific America Inc.' in California, USA, cementing its headquarters for the Americas. The new headquarters, based at the core medical company zone with over 10,000 square meters total floor area in Irvine, CA, will function as MicroPort®'s headquarters for the Americas, and house the Miracle Point® Southern California Innovation Center and Intelligent Manufacturing Base after the property purchased. The new headquarters will allow for MicroPort®'s further development in the Americas, especially in North America as a key component of their long-term strategy.

Mr. Yiyun Que, the First Vice President of Intelligent Manufacturing, Engineering and Global Supply Chain at MicroPort®, stated, "Once completed, the MicroPort® Americas Headquarters and the Southern California Intelligent Manufacturing Base will add to the existing R&D and manufacturing centers in Boston and Memphis, forming a 'MicroPort® US Triangle'. A stable regional presence will support the utilization of local resources more effectively and help us to engage more closely with US patients so as to meet their needs more quickly and efficiently. With the exciting news that the global shipments of MicroPort® coronary stent systems is expected to exceed 1.2 million units within this year, marking MicroPort® to become Top 2 in global market share, MicroPort® will step up efforts in advancing the clinical registration and commercialization processes of multiple innovative products, to make them available to patients in the Americas and the world as soon as possible."

Mr. Jonathan Chen, the Chief International Business Officer of MicroPort®, stated, "MicroPort® will continue to invest US$200 million in Southern California in the next five years, and create around 500 high-quality jobs to further support the local communities. Meanwhile, we will actively promote technological innovation within MicroPort® by leveraging the synergy of global innovation resources, to better serve the doctors in a more efficient and convenient manner and benefit patients around the world."

MicroPort

MicroPort® Launches Firehawk IN™ as First Local India-manufactured DES for India Market

Purple MicroPort Cardiovascular Private Limited (Purple MicroPort), an Indian joint venture company of MicroPort Scientific Corporation (MicroPort®) has officially launched for commercial sale the Firehawk IN™ Rapamycin Target Eluting Coronary Stent System (Firehawk IN™) for the Indian drug eluting stent (DES) market. Manufactured in Purple MicroPort's facility in Gujarat, India, Firehawk IN™ is the first drug eluting stent product MicroPort has manufactured in India.

"MicroPort®'s coronary products represented by the Firehawk® family of stents have a safety and quality comparable to that of international high-market share stent products, and have a large body of clinical data that show favorable results compared to the leading drug eluting stents in the world," noted Brian Lancelot, CEO of Purple MicroPort, "We are confident that Firehawk IN™ can be utilized by Indian interventional cardiologists to treat patients with coronary artery disease, and we are committed to partner with local medical communities through academic activities such as evidence-based medicine and professional education to support this launch."

MicroPort® Achieves 1 Million-Set Global Orders and Shipments of Coronary Stent Systems, Expected to be Global Top 2 in Market Share

Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®), a subsidiary of MicroPort Scientific Corporation (00853.HK), recently reached the milestone of 1 million global orders and shipments of its stent systems for the year of 2021. Amongst these stent systems are MicroPort®'s Firehawk®, Firebird2®, FireCondor™ and Firekingfisher™.

Mr. Yuegen Zhao, Senior Vice President of Supply Chain of MicroPort®, Senior Vice President of Supply Chain of MicroPort®, noted, "MicroPort® has a large-scale digital production capacity, with a combined annual output of 2 million sets of coronary stents and balloon catheters. Our global supply chain is expected to achieve a capacity of 5 million sets in 2 years, as well as a super production capacity of 10 million sets in 5 years, which will ensure that we meet the demand of the growing international markets."

Mr. Lei Jiang, President of MicroPort® Coronary, stated, "We are optimistic that MicroPort® will become Top 2 in the coronary stent global market share within this year, based on the global historical statistical data and this year's market data forecast. In order to accelerate the global market launch process of the new-generation MicroPort® coronary stents, and better balance business development and social responsibility, we have launched a new R&D center – the second-largest coronary manufacturing base outside of China – in Southern California, USA. Leveraging the talent and the industrial foundation of the medical industry cluster in Southern California, and relying on its unique advantages in the standard process of new product development and commercialization, MicroPort® is expected to develop more world-class products at a faster pace, allowing more patients to enjoy its high-tech, accessible solutions."

In regards to the international market, Dr. Linda Lin, First Vice President of Overseas Business of MicroPort®, noted, "With a product portfolio of proven quality, MicroPort®'s coronary stents have successfully entered more than 2,200 hospitals in nearly 40 countries worldwide, covering key markets in Asia Pacific, Europe and South America."

MicroPort

MicroPort® Coronary Balloon Dilation Catheters Firefighter™ and Firefighter™ NC Approved for Marketing in Colombia

Recently, Firefighter™ PTCA Balloon Catheter (Firefighter™) and Firefighter™ NC PTCA Balloon Catheter (Firefighter™ NC), developed by Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®), a subsidiary of MicroPort Scientific Corporation, have been approved for marketing in Colombia by the National Institute for Drug and Food Surveillance (INVIMA).

The approval for marketing of Firefighter™ and Firefighter™ NC further broadens the coronary product line of MicroPort® in Colombia. In the future, MicroPort® will continue to introduce more innovative, high-quality, and high-end medical devices into overseas markets, so that comprehensive disease treatment solutions can be provided to more patients worldwide.

MicroPort® Orthopedics Zirconium-Niobium Alloy Femoral Head Gains Access to China's Special Approval Procedure for Innovative Medical Devices

A zirconium-niobium alloy femoral head, designed and developed by Suzhou Minimally Invasive Orthopedics (Group) Co., Ltd. (MicroPort® Orthopedics), has been given access by the National Medical Products Administration (NMPA) of China to enter the 'Green Path', the special approval procedure for innovative medical devices. This marks a total of 25 products by MicroPort® or affiliated companies to have entered the through this approval pathway.

Mr. Zixin Weng, President of MicroPort® Orthopedics, said, "This zirconium-niobium alloy femoral head, developed by MicroPort® Orthopedics, is created using a design concept that is the first of its kind in China. It is expected to improve patients' post-operative satisfaction by extending the life of the hip prosthesis and reducing material wear. We will continue to optimize our product portfolio, with an aim of providing more total solutions for skeletal and muscle diseases to help more patients regain their health. "

MicroPort

Vflower™, First Venous Stent System by MicroPort® Endovastec, Gains Access to China's Special Approval Procedure for Innovative Medical Devices

The Vflower™ Venous Stent System (Vflower™), developed by Shanghai Bluevastec MedTech Co., Ltd. (Bluevastec™), has been given access by the National Medical Products Administration (NMPA) of China to enter the 'Green Path', the special approval procedure for innovative medical devices. This marks a total of 25 products by MicroPort® or affiliated companies that have entered the Green Path, 6 of which were developed by Endovastec™.

Qing Zhu, President of Endovastec™, stated, "There is a very promising market for venous products, however, there are currently only two venous stents available on the Chinese market. The approval of the Vflower™ Venous Stent System to enter the Green Path will accelerate its market launch process in China. This is of great significance in our effort to speed up research and innovation, promote the localization of premium medical devices and benefit more patients with peripheral vascular diseases."





Ryflumen®, First Peripheral High-Pressure Balloon Dilatation Catheter of Endovastec™, Approved for Marketing by NMPA

Shanghai VasoLutions MedTech Co. Ltd. (VasoLutions™), a wholly-owned subsidiary of Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) recently received a marketing registration certificate issued by the National Medical Products Administration (NMPA) for its Ryflumen® Peripheral High-Pressure Balloon Dilatation Catheter.

Dr. Lantao Guo, General Manager of VasoLutions™, stated, "We have been devoting ourselves to the field of peripheral vascular devices and rapidly improving our portfolio strategy. Currently, we have three peripheral arterial products including the Reewarm® PTX Drug-Coated Balloon Catheter. As the first high-pressure balloon dilatation catheter for peripheral intervention by Endovastec™, Ryflumen® has performed equally well compared to other mainstream competitive products in the market in terms of various performance indicators. It ensures effective dilatation of peripheral vascular lesions, allowing for reliable vascular preparation for subsequent treatments. "

MicroPort® NeuroTech Completes Strategic Financing with Shareholder Structure Optimization, as Foundation for Next-Step Global Expansion

MicroPort NeuroTech Limited (MicroPort® NeuroTech), a subsidiary of MicroPort Scientific Corporation (MicroPort®) that focusses on the development and promotion of innovative therapeutic solutions for cerebrovascular diseases, successfully entered a financing agreement of US$ 150 million in amount as planned, which brought to NeuroTech several renowned strategic investors including CICC Capital, HHF Capital, Broad Vision Funds, Runkun Partners and Prosperous Alliance. Meanwhile, Biolink Capital, which subscribed for US$70 million convertible bonds of NeuroTech in 2020, had its bond converted and made a follow-up investment.

Mr. Yiqun Wang, Executive Vice President and Director of Engineering Technology Center of MicroPort® NeuroTech stated, "Having been seeking development in the neurointerventional medical device industry for many years, NeuroTech has now become a total stroke solution provider with a global footprint. We have laid solid foundation for independent R&D and product commercialization. The entry of strategic partners during this round of financing is expected to provide more resources for our future R&D, production and industrial expansion. We are also confident that they will bring more vitality and possibilities for our future development."

Mr. Zhiyong Xie, President of MicroPort® NeuroTech, noted, "Globally, stroke is the second biggest cause of death, only next to cardiovascular diseases, and China has the highest incidence of stroke in the world. Over the past 30 years, the incidence of stroke in China has risen dramatically and younger patients have fallen victim to this illness. With accelerated progress of building stroke treatment centers in China, urgent demands are increasing for greater variety of neurointerventional products. MicroPort® NeuroTech will continue to broaden and deepen its product lines and form a systematic plan around hemorrhagic, ischemic, and accessory products to address the unmet clinical needs and provide more accessible medical solutions for patients of cerebrovascular diseases worldwide."

Mr. Bo Peng, Chairman of MicroPort® Greater China Executive Committee, Chief Marketing Officer, and Chairman of MicroPort® NeuroTech, commented, "This round of financing brought several renowned strategic investors that will lead to a modern shareholder structure and professional corporate governance for MicroPort® NeuroTech, while maintaining independent operation. We will work together with our investors to promote the development of the neurointerventional industry."

Mona Lisa Robotic Prostate Puncture System
Completes Enrollment of First Case for Clinical Trial

Shanghai Intbot Robotics Co., Ltd. (Shanghai Intbot), a joint venture of Shanghai MicroPort MedBot (Group) Co. Ltd. (MicroPort® MedBot) and Biobot Surgical Pte. Ltd. (Biobot Surgical), completed enrollment of the first case for their clinical trial of the Mona Lisa Robotic Prostate Puncture System (Mona Lisa). The enrolled case is the first robot-assisted prostate puncture biopsy in China, and was completed in Gulou Hospital Affiliated to Medical College of Nanjing University (Nanjing Gulou Hospital).

Mr. Yu Liu, Chief Business Officer of MicroPort® MedBot stated, "We appreciate the support from the expert teams at the three hospitals, and expect to complete the clinical trial series as quickly as possible and to the highest quality. We will continue to cooperate with clinical experts in the field of robot surgery and aim to transform the field of percutaneous puncture operations."

Dr. Chao He, President of MicroPort® MedBot commented, "It is through the continuous and collaborative efforts of the experts and the team at the clinical center, that we have successfully enrolled the first subject for the clinical trial of Mona Lisa prostate puncture positioning system. In the future, Shanghai Intbot will continue to strengthen its cooperation with experts, promote technological development, accomplish rapid product iteration and upgrade, and provide more doctors and patients with high-quality, accessible surgical solutions."

MicroPort

MicroPort® MedBot® Announces the Completion of the First Confirmatory Clinical Trial of the R-ONE® Vascular Interventional Surgical Robot in China

Cathbot (Shanghai) Robot Co., Ltd. (Shanghai Cathbot®), a joint venture between Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot®) and French company Robocath S.A.S (Robocath), announced today the completion of the first confirmatory clinical trial of the R-ONE® Vascular Interventional Surgical Robot (R-ONE®) at the 301st Hospital in China. This surgery, a robotic-assisted percutaneous coronary intervention (PCI), was successfully led by Professor Yundai Chen, Director of the Department of Cardiology, for a patient with acute coronary syndrome (ACS).

Dr. Philippe Bencteux, Chairman and Founder of Robocath, stated, "The success of the first confirmatory clinical trial of R-ONE® in China is the result of a joint effort and win-win partnership between Robocath and MicroPort® MedBot®. We also greatly appreciate the efforts of Prof. Yundai Chen and the team from Shanghai Cathbot®. This clinical trial marks the first step in the commercialization of robotic-assisted PCIs. Vascular interventional surgical robots, which feature a precise and efficient workflow, will disrupt traditional procedures, not only by improving the surgical safety for patients, but also by providing a safer working environment for clinicians."

Dr. Chao He, President of MicroPort® MedBot®, said, "With its continuous clinical development, confirmatory and market approval, R-ONE® will fill a gap in the field of robotic-assisted PCIs in China where no comparable products are available at the moment, bringing more benefits to doctors and patients."

MicroPort

MicroPort® Kewei Membrane Oxygenator Gains Access to China's Special Approval Procedure for Innovative Medical Devices

The Vitasprings® Spiral Diversion Integrated Membrane Oxygenator (Vitasprings®), developed by Dongguan Kewei Medical Instrument Co., Ltd. (MicroPort® Kewei), a subsidiary of MicroPort Scientific Corporation (MicroPort®), was given access by the National Medical Products Administration (NMPA) of China to enter the special approval procedure for innovative medical devices, also known as the 'Green Path'. As of the press release date, total of 25 products by MicroPort® or affiliated companies have entered the 'Green Path'.

Mr. Zhiguang Cheng, President of MicroPort Surgical (Shanghai) Co., Ltd., said, "As one of the first companies in China to focus on oxygenator research, MicroPort® Kewei always strives to develop quality products with independent intellectual property rights by adopting the design concept of boundless bionics. Vitasprings® has passed strict clinical tests on safety and efficacy, and all key indicators have demonstrated its world-leading quality, demonstrating our ability to design complex integrated structures and conduct hydrodynamic analysis for membrane oxygenators. In the future, through continuous technological innovation, MicroPort® Kewei will continue to improve the overall level of extracorporeal life support products, including oxygenators and premium supporting cannulae, to provide patients with better and more affordable extracorporeal life support solutions."

MicroPort® RehabTech TherMotion® Cryo-Thermo Compression Device Approved for Marketing in China

Suzhou MicroPort RehabTech (Group) Co. Ltd. (MicroPort® RehabTech), a subsidiary of MicroPort Scientific Corporation (MicroPort®), has recently obtained a registration certificate of medical devices issued by Jiangsu Drug Administration (JSDA) for its TherMotion® Cryo-Thermo Compression Device (TherMotion®). This is the company's first registration certificate for an active medical device since its inception.

Mr. Yi Luo, General Manager of MicroPort® RehabTech, commented, "At present, MicroPort® has acquired nearly 100 patents in rehabilitation medicine and has several products already commercially available. As the company's first active device approved for marketing, TherMotion® demonstrates the strength of MicroPort® RehabTech in providing a full range of equipment and consumables solutions for the acute phase of musculoskeletal rehabilitation."

MicroPort

Investor Newsletter

Issue 11 2021

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com